CardiaCast: New Hope in HF: The Evolving Evidence for SGLT2 Inhibitors

Jul 30, 2021   |  Alanna A Morris, MD, MSc; Javed Butler, MBBS, FACC; John J. V. McMurray, MD, FACC; Muthiah Vaduganathan, MD

Podcast

Font Size
A
A
A

In this episode, Alanna Morris, MD, MSc, FACC; Javed Butler, MBBS, FACC; John McMurray, MD, FACC; and Muthiah Vaduganathan, MD, FACC, discuss the role of sodium-glucose transport protein 2 inhibitors in the new hope in heart failure (HF). Visit the Clinical Spotlight Series: Shining a Light on New HF Pharmacotherapies online course page for more information and resources.

Educational support provided by AstraZeneca, Cytokinetics, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.




Clinical Topics: Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure

Keywords: CardiaCast, Heart Failure, Drug Therapy, Primary Prevention


< Back to Listings